Global InformationEpitopoietic Research Corporation information
 | This article contains content that is written like an advertisement. (July 2021) |
 | |
| Industry | Biotechnology |
|---|---|
| Founded | 2006 |
| Headquarters | Belgium |
Key people | Apostolos Stathopoulos (CEO) Vince Dell (Co-Founder and USA CFO) Thomas Chen (Chief Medical Officer) Virgil Schijns (Chief Scientific Officer) Joseph Elliot (Managing Director, ERC-USA) |
| Products | ERC1671 (Gliovac/Sitoiganap (EU)) |
| Website | www.erc-immunotherapy.com |
Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company that is specialized in the development of ERC1671 (Gliovac, Sitooiganap (EU)), a treatment for Glioblastoma multiforme, which is the most aggressive form of brain cancer. In 2019 ERC provided treatment under the US Federal Right-to-try law.[1][2][3][4][5][6]
- ^ "Epitopoietic Research Corporation". ERC. 2020-04-09. Retrieved 2020-07-02.
- ^ "k8fT0MoqyMcug16mplqDtQ2". S&P Global Market Intelligence. 2019-11-26. Retrieved 2020-07-02.
- ^ ERC-USA (2019-11-19). "ERC-USA Sponsors Ancillary Meeting to Discuss Outcomes from Its Clinical Trial and Right To Try Patient Experience of ERC1671 in Recurrent Glioblastoma". GlobeNewswire News Room. Retrieved 2020-07-02.
- ^ Bota, Daniela A; Alexandru-Abrams, Daniela; Pretto, Chrystel; Hofman, Florence M; Chen, Thomas C; Fu, Beverly; Carrillo, Jose A; Schijns, Virgil EJC; Stathopoulos, Apostolos (2008-06-26). "Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report". The Permanente Journal. 19 (2): 41–6. doi:10.7812/TPP/14-042. PMC 4403580. PMID 25785641.
- ^ "ERC Belgium Submits Marketing Authorization Application to European Medicines Agency (EMA) for Glioblastoma Immunotherapy, SITOIGANAP". Yahoo Finance. 2018-08-26. Retrieved 2020-07-02.
- ^ Michelle Fay Cortez (2019-01-10). "Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law". www.bloomberg.com.